The primary endpoint was difference between treatment arms in Framingham 10 year CHD risk after 52 weeks ; secondary assessments included difference in calculated CHD risk at Week 16 ; SCORE cardiovascular mortality ( Week 16 and 52 ) ; blood pressure ( BP ) / lipid parameters ; adverse events ( AEs ) .
